Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, quetiapine (Seroquel XL®) cannot be endorsed for use within NHS Wales for the prevention of the recurrence of bipolar disorder. |
||
|
||
Medicine details |
||
| Medicine name | quetiapine (Seroquel XL®) | |
| Formulation | prolonged-release tablet | |
| Reference number | 613 | |
| Indication | For the prevention of the recurrence of bipolar disorder. |
|
| Company | AstraZeneca UK Ltd | |
| BNF chapter | Central nervous system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | Not available | |
| Date of issue | 22/04/2010 | |